Literature DB >> 22219178

MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells.

Cristina Garrido1, Laura Paco, Irene Romero, Enrique Berruguilla, Julia Stefansky, Antonia Collado, Ignacio Algarra, Federico Garrido, Angel M Garcia-Lora.   

Abstract

The alteration of MHC class I (MHC-I) expression is a frequent event during cancer progression, allowing tumor cells to evade the immune system. We report that the loss of one major histocompatibility complex haplotype in human melanoma cells not only allowed them to evade immunosurveillance but also increased their intrinsic oncogenic potential. A second successive defect in MHC-I expression, MHC-I total downregulation, gave rise to melanoma cells that were more oncogenic per se in vivo and showed a higher proliferation rate and greater migratory and invasive potential in vitro. All these processes were reversed by restoring MHC-I expression via human leukocite antigen-A2 gene transfection. MHC-I cell surface expression was inversely correlated with intrinsic oncogenic potential. Modifications in the expression of various cell cycle genes were correlated with changes in MHC-I expression; the most important differences among the melanoma cell lines were in the transcriptional level of AP2-alpha, cyclin A1 and p21WAF1/CIP1. According to these results, altered MHC-I expression in malignant cells can directly increase their intrinsic oncogenic and invasive potential and modulate the expression of cell cycle genes. These findings suggest that human leukocite antigen class I molecules may act directly as tumor suppressor genes in melanoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22219178     DOI: 10.1093/carcin/bgr318

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  25 in total

Review 1.  Targeting cancer-specific mutations by T cell receptor gene therapy.

Authors:  Thomas Blankenstein; Matthias Leisegang; Wolfgang Uckert; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2015-02-27       Impact factor: 7.486

Review 2.  Immunoplasticity in cutaneous melanoma: beyond pure morphology.

Authors:  Francesca Maria Bosisio; Joost J van den Oord
Journal:  Virchows Arch       Date:  2017-01-05       Impact factor: 4.064

3.  Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.

Authors:  Raghavendra Gowda; Gregory Kardos; Arati Sharma; Sanjay Singh; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2016-12-21       Impact factor: 6.261

Review 4.  MHC heterogeneity and response of metastases to immunotherapy.

Authors:  Ignacio Algarra; Federico Garrido; Angel M Garcia-Lora
Journal:  Cancer Metastasis Rev       Date:  2021-04-15       Impact factor: 9.264

5.  Prediction of Major Histocompatibility Complex Binding with Bilateral and Variable Long Short Term Memory Networks.

Authors:  Limin Jiang; Jijun Tang; Fei Guo; Yan Guo
Journal:  Biology (Basel)       Date:  2022-06-01

6.  ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.

Authors:  Claire Y Oh; Martin G Klatt; Christopher Bourne; Tao Dao; Megan M Dacek; Elliott J Brea; Sung Soo Mun; Aaron Y Chang; Tatyana Korontsvit; David A Scheinberg
Journal:  Cancer Immunol Res       Date:  2019-09-20       Impact factor: 11.151

7.  LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma.

Authors:  Jacky T Yeung; Ronald L Hamilton; Koji Ohnishi; Maki Ikeura; Douglas M Potter; Marina N Nikiforova; Soldano Ferrone; Regina I Jakacki; Ian F Pollack; Hideho Okada
Journal:  Clin Cancer Res       Date:  2013-02-11       Impact factor: 12.531

8.  Genetic evolution of T-cell resistance in the course of melanoma progression.

Authors:  Antje Sucker; Fang Zhao; Birgit Real; Christina Heeke; Nicola Bielefeld; Stefan Maβen; Susanne Horn; Iris Moll; Raffaela Maltaner; Peter A Horn; Bastian Schilling; Francesco Sabbatino; Volker Lennerz; Matthias Kloor; Soldano Ferrone; Dirk Schadendorf; Christine S Falk; Klaus Griewank; Annette Paschen
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

Review 9.  Biomarkers of therapeutic response with immune checkpoint inhibitors.

Authors:  Poorva Bindal; Jhanelle E Gray; Theresa A Boyle; Vaia Florou; Sonam Puri
Journal:  Ann Transl Med       Date:  2021-06

10.  Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells.

Authors:  Bishu Sapkota; Charles E Hill; Brian P Pollack
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.